Table 1 Analytical and clinical response to current biological agent
From: Switching to an alternative biological agent in juvenile idiopathic arthritis (II)
| Â | Ph-VAS | ESR | CRP | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Â | Initial* | End* | Ûµ | p | Initial* | End* | Ûµ | p | Initial* | End* | Ûµ | p |
ETA | 3.25 | 0.5 | -6 | 0.00 | 28 | 12 | -5 | 0.00 | 13.2 | 2.3 | -5 | 0.00 |
ADA | 2.42 | 0.4 | -3 | 0.01 | 17 | 13 | -1 | 0.26 | 5.58 | 1.2 | -2 | 0.06 |
AK | 5.36 | 0.00 | -3 | 0.01 | 62 | 9 | -2 | 0.02 | 69.5 | 2.9 | -2 | 0.03 |
TCZ | 6.45 | 0.86 | -3 | 0.01 | 46 | 4 | -3 | 0.01 | 95.6 | 0.6 | -3 | 0.01 |
IFX | 4.9 | 0.00 | Â | Â | 47 | 6 | Â | Â | 32.8 | 0.9 | Â | Â |